Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
Provided By GlobeNewswire
Last update: Mar 14, 2025
Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108
Read more at globenewswire.comNASDAQ:PALI (8/5/2025, 10:54:04 AM)
1.0199
-0.02 (-1.93%)
Find more stocks in the Stock Screener
PALI Latest News and Analysis
